One such product gaining attention in 2025 is Herpesyl, a nutritional supplement that claims to not just suppress herpes ...

IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from ...

Built with these industry themes in mind, Tevogen Bio exemplifies how American biotech can remain competitive and thrive amid growing concerns surrounding affordability, efficiency, and global ...

A live audio webcast of the fireside chat presentation will be available at and an archived replay will be accessible in the Investors section of the Keros website at (opens in a new tab) for up to ...

a. Vaxart is at risk of being delisted from Nasdaq since the Company’s share price is not in compliance with their minimum $1.00 bid price requirement. A reverse split of the Company’s common stock ...

Webcast Link Instructions A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: ...

Foresight Diagnostics will be available for 1x1 meetings on June 3 rd and 4 th. To schedule a meeting, please contact Patrick Charles at LifeSci Advisors, [email protected].

Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in ...

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...

IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...